A practical reference on 内毒素: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
== Analysis == The chemical analysis of fatty acids in lipids typically begins with an interesterification step that breaks down their original esters (triglycerides, waxes, phospholipids etc.) and converts them to methyl esters, which are then separated by gas chromatography or analyzed by gas chromatography and mid-infrared spectroscopy. Separation of unsaturated isomers is possible by silver ion complemented thin-layer chromatography. Other separation techniques include high-performance liquid chromatography (with short columns packed with silica gel with bonded phenylsulfonic acid groups whose hydrogen atoms have been exchanged for silver ions). The role of silver lies in its ability to form complexes with unsaturated compounds.
Aspergillus luchuensis was first described in 1901 by Tamaki Inui at the University of Tokyo. Genichiro Kawachi isolated a colourless mutant of A. luchuensis (black kōji) in 1918 and named it Aspergillus kawachii (white kōji). Aspergillus sojae was first described as a distinct species in kōji in 1944. Initially, Aspergillus sojae was considered a variety of Aspergillus parasiticus because, unlike the other fungi of kōji, it had never been isolated from the soil.
=== Bioactivation of antitumor agents === Several anti-tumor agents such as mitosenes, indolequinones, aziridinylbenzoquinones and β-lapachone have been designed be bioactivated by NQO1 from various prodrugs. The high levels of NQO1 expression in many human solid tumors compared to normal tissue ensures their selective activation within tumor cells.
Sources: en.wikipedia.org
== Basic research == β-Caryophyllene is under basic research for its potential action as an agonist of the cannabinoid receptor type 2 (CB2 receptor). In other basic studies, β-caryophyllene has a binding affinity of Ki = 155 nM at the CB2 receptors. β-Caryophyllene has the highest cannabinoid activity compared to the ring opened isomer α-caryophyllene humulene which may modulate CB2 activity. To compare binding, cannabinol binds to the CB2 receptors as a partial agonist with an affinity of Ki = 126.4 nM, while delta-9-tetrahydrocannabinol binds to the CB2 receptors as a partial agonist with an affinity of Ki = 36 nM.
Smoking Inadequate self-performed oral hygiene Many sites of bony and tissue defects Unable to achieve wound closure after surgery due to insufficient soft tissues Severe furcation involvement, i.e. grade 3 Systemic diseases, e.g. diabetes
== Metabolic pathways and products == Zearalenone is metabolically transformed to α-zearalenol (α-Zel) or (α-Zol), β-zearalenol (β-Zel) or (β-Zol), α-zearalanol (α-Zal), β-zearalanol (β-Zal), and zearalanone (ZAN) in animals. The relative composition of these metabolic products varies by species. In pigs, cows and ducks, α-Zel is the dominant form detected. In humans, both α-Zel and β-Zel are seen in urine samples, with the beta form being prevalent. In chickens, β-Zel is the dominant form and in plant cells, the metabolic product zeralenonne-14-O-β-glucoside has been detected. Additionally, in the organs of animals these metabolic products are further modified to yield zearalenone-14-glucuronide (ZEN-14GlcA), α-zearalenol-glucuronide (α-Zel-14G) and β-zearalenol-glucuronide (β-Zel-14G).
Sources: en.wikipedia.org
=== Vaccine development and advance market commitments === Advance Market Commitments (AMCs) aim to overcome market failure by making an advance pledge that if a vaccine for a certain condition is developed, meeting certain specifications, donors will buy a certain number of doses. Gavi seeks to design its AMCs in a way that encourages a competitive market. Gavi has been particularly successful at promoting the uptake of newer vaccines.
In September 1936, Fry's released an aerated Crunchie bar made entirely of chocolate. They justified this move as not breaching the patent, saying it was not a block but a bar. As Aero sales began to dip, Rowntree's brought out variants, selling the first aerated chocolates with fruit and nut inclusions. After Fry's launched a second aerated chocolate in August 1937 called Ripple, Rowntree's had to decide whether they wanted to try to enforce their patent. By this time, Nestlé and Fry's had joined Cadbury in having expressed a willingness to challenge the patent in the courts despite it being officially approved by the patent office. On legal advice that there was a 50% likelihood of success in a court challenge, and the threat of court proceedings causing bad publicity, Rowntree's entered negotiations with other chocolate makers to discuss licensing aerated chocolate. Rival companies were dominant in the proceedings dialogues, and Rowntree's ultimately agreed to licence aerated chocolate from June 1938 under the conditions that chocolate makers pay a sum with the release of new aerated chocolate lines and a 0.5% royalty on sales. After this agreement was put in place, Cadbury only released aerated chocolate products in overseas dominions where Aero was not established. Nestlé-produced aerated chocolates included a chocolate called Bubblo, made in the UK for export to New Zealand under a New Zealand patent. Aerated chocolate was already being sold in some overseas markets, by 1936 for instance, Aero was being successfully exported to Australia.
Battle of Hébuterne — French attacks on the southern flanks became disorganized, with one German patrol able to take 100 French prisoners. U.S. President Woodrow Wilson sent Germany the second of three letters related to the sinking of the RMS Lusitania in May, rejecting Germany's argument the British blockade was illegal and that the Lusitania was carrying munitions. United States Secretary of State William Jennings Bryan resigned over disagreement regarding his nation's handling of the RMS Lusitania sinking. Second Battle of Garua — After nearly 10 days of siege from British and French forces, close to half of the native colonial troops under German command in forts around Garua, German Cameroon began to mutiny or desert their posts. British colonial force cracked down on rioters in Ceylon, resulting in 116 dead. British cruiser HMS Dublin was torpedoed and damaged in the Adriatic Sea off Albania by Austro-Hungarian submarine SM U-4 with the loss of 12 of her 440 crew. HMS Dublin was subsequently repaired and returned to service. The Georgia Prison Commission denied an application to commute the death sentence of Leo Frank in a 2–1 vote, who was convinced in 1913 for the murder of 13-year old Mary Phagan. British naval forces occupied the island of Kamaran in the Red Sea off the coast what is now Yemen. The French Army established the Marine Infantry Tank Regiment. Born: Les Paul, American musician, inventor of the solid body electric guitar; as Lester William Polsfuss, in Waukesha, Wisconsin, United States (d. 2009)
transcript of unknown function (TUF) Any RNA transcript whose function is unclear. Such transcripts may include functional non-coding RNAs which have not yet been studied in detail as well as spurious transcripts without any definite function. The DNA sequences from which TUFs are transcribed are generally located in intergenic or intronic regions of the genome. See also junk RNA.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.